Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

The Phase 1 study of PRT12396 is an open-label, multi-center, safety and efficacy study in patients with high-risk polycythemia vera (PV) and intermediate and high-risk myelofibrosis (MF). The primary ...
Seeking Alpha

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower ...

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics (VERV), a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of ...